Description

Truvada Emtricitabine and Tenofovir Disoproxil Fumarate Tablets combine two potent antiretroviral agents—emtricitabine 200?mg and tenofovir disoproxil fumarate 300?mg per tablet. These synthetic nucleoside/nucleotide analogs inhibit HIV?1 reverse transcriptase and viral DNA synthesis. Widely used for treatment and prevention of HIV?1, in research it is applied to study viral replication, drug resistance, PrEP efficacy, and combination antiviral therapy. Manufactured under licence HJ20200025 by Patheon Inc., Canada, each film?coated tablet delivers precise dosing and consistent bioactivity. Supplied in packs of 30 tablets. Intended exclusively for laboratory research use only.

Product Specifications

Mechanism of Action & Research Applications

Truvada Emtricitabine and Tenofovir Disoproxil Fumarate Tablets function by dual inhibition of HIV?1 reverse transcriptase and viral DNA polymerase activity, disrupting viral replication cycle. Emtricitabine acts as a cytidine analog to inhibit RT enzyme; tenofovir disoproxil fumarate is converted to tenofovir in vivo to inhibit polymerase activity. In research applications, Truvada tablets are used to model antiviral efficacy in HIV?1 infection settings, evaluate PrEP regimens, assess resistance mutations, and explore combination therapeutic strategies. Suitable for virology assays, pharmacodynamics studies, and preclinical drug screening. For laboratory research use only.

Side Effects (For Reference Only in Models)

In experimental models or preclinical references, possible observations include mild fatigue, gastrointestinal discomfort (nausea, diarrhea), headache, skin pigmentation changes, transient kidney or liver enzyme alterations, and rare metabolic acidosis. Animal or cell model results should inform dose escalation and safety monitoring.

Disclaimer

Truvada Emtricitabine and Tenofovir Disoproxil Fumarate Tablets 200?mg/300?mg are strictly intended for laboratory research use only. Not for human or veterinary therapeutic use.